How did Guardant's revenue and profitability trend in the second quarter of 2025?

Revenue grew 31% to $232.1M. Non-GAAP gross margin improved to 66% from 60%, and non-GAAP net loss narrowed to $55.0M from $58.5M. GAAP net loss was $99.9M, slightly better than $102.6M a year earlier, and the company remains unprofitable on both a GAAP and non-GAAP basis.

Why did management raise full-year revenue guidance, and what drove the change?

Guidance rose to $915-$925M from $880-$890M. The largest change came from Screening, where revenue guidance increased to $55-$60M from $40-$45M on higher expected Shield volumes. Oncology growth expectations also increased to about 20% from 18%, and Biopharma & Data growth was raised to the mid-teens from low double digits.

How much cash is Guardant burning, and when does the core business become cash-flow positive?

Full-year 2025 free cash flow burn is guided to $225-$235M, an improvement from $275M in 2024. About $200M of that is attributable to Shield Screening. Management expects the business excluding Screening to reach free cash flow breakeven in Q4 2025. Cash, cash equivalents and restricted cash were $735.5M at June 30, 2025.

What are the risks around the Shield screening investment?

Shield requires continued heavy investment in commercial infrastructure, with non-GAAP operating expense guidance raised to $840-$850M. Screening is expected to consume roughly $200M of cash in 2025. Its success depends on sustaining test volume growth and reimbursement, and the stockholders' deficit widened to $(305.5)M at quarter end, which increases reliance on continued financing access.

Are the Q2 improvements in free cash flow and EBITDA sustainable?

Part of the year-over-year free cash flow improvement reflects timing differences, since the annual bonus was paid in Q1 2025 versus Q2 2024, so it is not a pure run-rate gain. Adjusted EBITDA improvement and gross margin expansion are more structural. Investors should note that six-month free cash flow was still $(133.1)M, and that management's full-year burn guidance implies significant cash use in the second half.

GH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Guardant Health (GH) reported strong second quarter 2025 results, with total revenue of $232.1 million^a, up 31% year over year.

Growth was broad-based: Oncology revenue rose 22% to $158.7 million^b on 30% test volume growth, Biopharma & Data revenue grew 28% to $56.0 million, and Shield screening contributed $14.8 million from roughly 16,000 tests. Non-GAAP gross margin expanded to 66% from 60%, and non-GAAP net loss narrowed to $55.0 million ($0.44 per share) from $58.5 million. Adjusted EBITDA loss improved to $51.9 million from $61.9 million, and free cash flow improved to $(65.9) million from $(99.1) million, though the year-over-year improvement was partly driven by timing of annual bonus payouts.

Management raised 2025 revenue guidance to $915^c-$925 million (24%-25% growth), up from $880-$890 million. Screening revenue guidance rose to $55-$60 million on 68,000-73,000 Shield tests, and Oncology growth is now expected near 20%. Non-GAAP operating expenses guidance increased to $840-$850 million, reflecting reinvestment of incremental Screening gross profit into the Shield commercial build-out.

Management continues to expect full-year free cash flow burn of $225^d-$235 million, including roughly $200 million of Screening cash burn, and expects the non-Screening business to reach free cash flow breakeven in Q4 2025. Key watch items for investors are the continued cash burn tied to Shield, the GAAP net loss of $99.9 million for the quarter, and the sustainability of Oncology reimbursement gains.

Cash, cash equivalents and restricted cash totaled $735.5 million at June 30, 2025, while convertible senior notes principal had declined to $1.09 billion. Stockholders' deficit widened to $(305.5) million, and the company has not yet reached GAAP profitability.

02—Key points

Key Highlights

Total Q2 2025 revenue of $232.1M, up 31% YoY, led by Oncology (+22% to $158.7M), Biopharma & Data (+28% to $56.0M), and first meaningful Shield Screening revenue of $14.8M.
2025 revenue guidance raised to $915-$925M (24%-25% growth) from $880-$890M, the second upward revision cited in the release.
Non-GAAP gross margin expanded to 66% from 60% a year earlier; Guardant360 Tissue ASP reached roughly $2,000, three years ahead of its 2028 target.
Screening guidance raised to $55-$60M revenue on 68,000-73,000 Shield tests, versus prior $40-$45M and 52,000-58,000 tests.
Non-GAAP operating expense guidance increased to $840-$850M to fund accelerated Shield commercial infrastructure, while free cash flow burn guidance held at $225-$235M.
Adjusted EBITDA loss narrowed to $51.9M from $61.9M, and Q2 free cash flow improved to $(65.9)M from $(99.1)M, partly due to bonus payment timing.
Pipeline and regulatory progress included FDA Breakthrough Device Designation for Shield MCD, NCI Vanguard study enrollment, Shield inclusion in NCCN colorectal screening guidelines, and a Reveal breast cancer MolDx submission.

03—Questions

Frequently Asked Questions

How did Guardant's revenue and profitability trend in the second quarter of 2025?
Revenue grew 31% to $232.1M. Non-GAAP gross margin improved to 66% from 60%, and non-GAAP net loss narrowed to $55.0M from $58.5M. GAAP net loss was $99.9M, slightly better than $102.6M a year earlier, and the company remains unprofitable on both a GAAP and non-GAAP basis.
Why did management raise full-year revenue guidance, and what drove the change?
Guidance rose to $915-$925M from $880-$890M. The largest change came from Screening, where revenue guidance increased to $55-$60M from $40-$45M on higher expected Shield volumes. Oncology growth expectations also increased to about 20% from 18%, and Biopharma & Data growth was raised to the mid-teens from low double digits.
How much cash is Guardant burning, and when does the core business become cash-flow positive?
Full-year 2025 free cash flow burn is guided to $225-$235M, an improvement from $275M in 2024. About $200M of that is attributable to Shield Screening. Management expects the business excluding Screening to reach free cash flow breakeven in Q4 2025. Cash, cash equivalents and restricted cash were $735.5M at June 30, 2025.
What are the risks around the Shield screening investment?
Shield requires continued heavy investment in commercial infrastructure, with non-GAAP operating expense guidance raised to $840-$850M. Screening is expected to consume roughly $200M of cash in 2025. Its success depends on sustaining test volume growth and reimbursement, and the stockholders' deficit widened to $(305.5)M at quarter end, which increases reliance on continued financing access.
Are the Q2 improvements in free cash flow and EBITDA sustainable?
Part of the year-over-year free cash flow improvement reflects timing differences, since the annual bonus was paid in Q1 2025 versus Q2 2024, so it is not a pure run-rate gain. Adjusted EBITDA improvement and gross margin expansion are more structural. Investors should note that six-month free cash flow was still $(133.1)M, and that management's full-year burn guidance implies significant cash use in the second half.

04—Continue

← View all 8-K filings